Epilepsy
Saniona comments on their new chapter in epilepsy treatment
Saniona has selected SAN2668 as its first-in-class clinical candidate for epilepsy, following strong preclinical results that demonstrated robust efficacy...
Saniona has started dosing in the SAN711 study
Saniona has begun dosing the first trial subjects...
Saniona CEO: “SAN2355 is a very promising candidate for commercialization”
Saniona has communicated important preclinical progress in the development...
Saniona comments on approval to initiate epilepsy study
Saniona has received approval to commence a...
CLS receives additional order from ClearPoint Neuro
Just before the midsummer weekend, Clinical Laserthermia System receives a...
She is CombiGene's new CSO
CombiGene's former Director Preclinical Development Annika Ericsson takes...
CombiGene's CEO comments on patent approvals in Australia and India
CombiGene has been granted patents in Australia and India...
Orphazyme comments on its holding in CombiGene
Orphazyme has acquired 10 percent of the shares in...
Saniona on the new epilepsy candidate SAN2355
Saniona ended 2023 by choosing SAN2355 as...
Saniona made further progress in Q3
Saniona's Q3 report summarizes a period of increased activity...
Saniona CEO: “Selectivity is the cornerstone of future epilepsy treatments”
On Tuesday morning, Saniona was able to announce progress in its...
CombiGene's CEO on the terminated Spark agreement
CombiGene was reached over the weekend by the news that Spark...